Low Potassium Dialysate Improves Hyperkalemia in ESRD patients
Hyperkalemia is a modifiable risk factor for sudden cardiac death, a leading cause of mortality in hemodialysis patients. A study published in the Clinical Kidney Journal on December 17, 2020, suggests that a low potassium bath for the treatment of severe hyperkalemia (>6.5 mmol/L) in hospitalized end-stage renal disease (ESRD) patients are associated with decreased in-hospital mortality or cardiac arrest.
Pre-dialysis hyperkalemia is associated with higher mortality in ESRD patients on maintenance hemodialysis (HD) in the outpatient setting. The optimal treatment of hyperkalemia in hospitalized ESRD patients is nonexistent in literature which has prompted studies from outpatient dialysis to be extrapolated to inpatient care. Therefore, researchers of the University of Wisconsin School of Medicine and Public Health, USA, conducted a study to determine whether low potassium dialysate 1 meq/L is associated with higher mortality in hospitalized ESRD patients with severe hyperkalemia (serum potassium > 6.5 mmol/L).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.